Post-ablation recurrence in hepatocellular carcinoma: molecular pathogenesis and targeted therapeutic innovations

肝细胞癌消融术后复发:分子发病机制和靶向治疗创新

阅读:1

Abstract

Hepatocellular carcinoma (HCC) is one of the most common types of cancer worldwide. It is characterized by an extremely poor prognosis. Radiofrequency ablation (RFA) and microwave ablation (MWA) have become the main local therapies for early HCC. Nevertheless, the high recurrence rate is a key factor that limits the efficacy of thermal ablation. Numerous studies have suggested that HCC recurrence after thermal ablation involves many mechanisms. These include remodeling of immunosuppressive microenvironment, evasion of programmed cell death, metabolic reprogramming, reprogramming of metabolic adaptation, activation of epigenetic aberrations, acquisition of stemness traits, enhancement of epithelial-mesenchymal transition (EMT), induction of angiogenesis, and regulation by non-coding RNAs. To tackle these underlying mechanisms, precision intervention strategies have been gradually developed. These included, but were not limited to, immune-targeted therapy, modulation of cell death pathways, regulation of metabolic pathways, epigenetic therapeutic strategies, stem cell inhibition interventions, EMT reversal therapy, anti-angiogenesis interventions, and multi-target combination strategies. Our review systematically summarizes the research progress from 2017 to 2025, classifying the multidimensional molecular mechanisms and precision intervention strategies for HCC recurrence following thermal ablation. This provides a theoretical foundation for individualized comprehensive treatment and future research directions.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。